Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Supplements topic
No spam. Unsubscribe anytime.
Audience health consultant urges FDA attention to supplements, panel says topic is out of scope for generics session
Summary
A health care consultant urged FDA attention to supplement sourcing, extraction toxicity and risks for patients on multiple medications; panelists said supplements/compounding are regulated differently from generics and suggested docket submissions or offline engagement.
A health care consultant in the audience urged FDA panelists to consider the safety of widely used dietary supplements and the effects of co‑formulations on older adults with high pill burdens. The consultant warned that sourcing and extraction methods for some supplements can be toxic and highlighted a risk that supplements such as red yeast rice could interact dangerously with prescription statins.
Panelist Dr. Kozak responded that compounding and supplements are regulated differently from brand‑name and generic drugs and that the panel’s expertise in this session was focused on generics. "It's slightly out of scope of what the scope of this sort of discussion is," Kozak said, and encouraged submitting detailed information to the regulatory docket or following up offline so the appropriate reviewers can consider the issues.
Why it matters: The exchange separated public safety concerns raised by an expert in the audience from the narrower remit of the generic drug discussion. The panel did not commit to policy changes in the session; instead it pointed the commenter to formal channels for regulatory input.
